Objective To investigate the expression and clinical significance of CD117、an nestin in triple negative breast carcinoma. Methods Pathological sections of tumor tissues from breast cancer patients were collected in our hospital between 2010 and 2012. Total 50 cases negative for ER、PR、HER2 were randomly selected as experimental group. Other 50 general breast cancer cases were randomly selected as control group. The expression of CD117 and Nestin was detected by immunohistochemistry. Results The expression of CD117 and Nestin in the experimental group was higher than that in the control group(P < 0.05). Conclusions The expression of CD117 and Nestin is higher in the triple negative breast carcinomas, which is closely related to the occurrence of this disease.